Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Robert Moot"'
Autor:
Sunil S. Raikar, Lauren C. Fleischer, Robert Moot, Andrew Fedanov, Na Yoon Paik, Kristopher A. Knight, Christopher B. Doering, H. Trent Spencer
Publikováno v:
OncoImmunology, Vol 7, Iss 3 (2018)
Relapsed T-cell malignancies have poor outcomes when treated with chemotherapy, but survival after allogeneic bone marrow transplantation (BMT) approaches 50%. A limitation to BMT is the difficulty of achieving remission prior to transplant. Chimeric
Externí odkaz:
https://doaj.org/article/595175915e694c6f9cbda7b8ad257be9
Autor:
Robert Moot, Sunil S Raikar, Lauren Fleischer, Melissa Querrey, Daniel E Tylawsky, Hirotomo Nakahara, Christopher B Doering, H Trent Spencer
Publikováno v:
Molecular Therapy: Oncolytics, Vol 3, Iss C (2016)
Chimeric antigen receptors (CARs) are used to redirect effector cell specificity to selected cell surface antigens. Using CARs, antitumor activity can be initiated in patients with no prior tumor specific immunity. Although CARs have shown promising
Externí odkaz:
https://doaj.org/article/34f8ba2e3b274917b2c74c753ebd8320
Autor:
Mohammad Al‐Diery, Asiri Arachchi, Binura Buwaneka Wijesinghe Lekamalage, Preekesh Suresh Patel, Andrew Robert Moot
Publikováno v:
ANZ Journal of Surgery.
Autor:
Susan P. Foy, Kyle Jacoby, Daniela A. Bota, Theresa Hunter, Zheng Pan, Eric Stawiski, Yan Ma, William Lu, Songming Peng, Clifford L. Wang, Benjamin Yuen, Olivier Dalmas, Katharine Heeringa, Barbara Sennino, Andy Conroy, Michael T. Bethune, Ines Mende, William White, Monica Kukreja, Swetha Gunturu, Emily Humphrey, Adeel Hussaini, Duo An, Adam J. Litterman, Boi Bryant Quach, Alphonsus H. C. Ng, Yue Lu, Chad Smith, Katie M. Campbell, Daniel Anaya, Lindsey Skrdlant, Eva Yi-Hsuan Huang, Ventura Mendoza, Jyoti Mathur, Luke Dengler, Bhamini Purandare, Robert Moot, Michael C. Yi, Roel Funke, Alison Sibley, Todd Stallings-Schmitt, David Y. Oh, Bartosz Chmielowski, Mehrdad Abedi, Yuan Yuan, Jeffrey A. Sosman, Sylvia M. Lee, Adam J. Schoenfeld, David Baltimore, James R. Heath, Alex Franzusoff, Antoni Ribas, Arati V. Rao, Stefanie J. Mandl
Publikováno v:
Nature, vol 615, iss 7953
T cell receptors (TCRs) enable T cells to specifically recognize mutations in cancer cells1–3. Here we developed a clinical-grade approach based on CRISPR–Cas9 non-viral precision genome-editing to simultaneously knockout the two endogenous TCR g
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd691b6fa2cf73c26cc536f7201c6b0c
https://escholarship.org/uc/item/2g96s8v7
https://escholarship.org/uc/item/2g96s8v7
Autor:
Cristina Puig Saus, Barbara Sennino, Songming Peng, Zheng Pan, Benjamin Yuen, Bhamini Purandare, Kyle Jacoby, Olivier Dalmas, Duo An, Boi Quach, Clifford Wang, Huiming Xia, Sameeha Jilani, Diana Nguyen, Kevin Shao, Claire McHugh, John Greer, Phillip Peabody, Saparya Nayak, Jonaathan Hoover, Sara Said, Susan Foy, Andrew Conroy, Michael Yi, Christine Shieh, William Lu, Katharine Heeringa, Yan Ma, Shahab Chizari, Melissa Pilling, Marc Ting, Ramya Tunuguntla, Salemiz Sandoval, Robert Moot, Theresa Hunter, Sidi Zhao, Justin Saco, Ivan Perez-Garcilaso, Agustin Vega-Crespo, Ignacio Baselga, Gabriel Abril-Rodriguez, Grace Cherry, Deborah Wong, Jasreet Hundal, Bartosz Chmielowski, Daniel Speiser, Michael Bethune, Xiaoyan Bao, Alena Gros, Obi Griffith, Malachi Griffith, James Heath, Alex Franzusoff, Stefanie Mandl, Antoni Ribas
Publikováno v:
Regular and Young Investigator Award Abstracts.
Autor:
Carlomaurizio Montecucco, Rieke Alten, Robert Moots, Peggy Jacques, Helga Radner, Harald E Vonkeman, Nicolas Krucien, Sebastian Heidenreich, Katrien Van Beneden, Juan Carlos Nieto-González, Chiara Whichello
Publikováno v:
RMD Open, Vol 10, Iss 1 (2024)
Objective Understanding preferences of patients with rheumatoid arthritis (RA) can facilitate tailored patient-centric care. This study elicited trade-offs that patients with RA were willing to make during treatment selection.Methods Patients with RA
Externí odkaz:
https://doaj.org/article/055575b73ad9497386ed521caaa9b66b
Autor:
Boi Quach, Justin Saco, Katharine Heeringa, Bhamini Purandare, Barbara Sennino, Songming Peng, Zheng Pan, Yan Ma, Diana Nguyen, Alex Franzusoff, Huiming Xia, Antoni Ribas, Christine Shieh, Kyle Jacoby, Olivier Dalmas, William Lu, Sameeha Jilani, Robert Moot, Duo An, Cristina Puig-Saus, Jasreet Hundal, Stefanie Mandl, Malachi Griffith, Andrew Conroy, Sidi Zhao
Publikováno v:
Cancer Research. 80:NG11-NG11
In infectious disease, polyclonal T cell responses against immunodominant epitopes drive successful immune responses. In cancer, neoepitopes (neoE) derived from non-synonymous mutations, similarly to the immunodominant epitopes in viral infections, a
Autor:
Robert Moot, Christopher B. Doering, Jennifer M. Johnston, D Whitehead, Gabriela Denning, Harold Trent Spencer, J M Le Doux, Jordan E Shields
Publikováno v:
Gene Therapy. 21:1008-1020
A difficulty in the field of gene therapy is the need to increase the susceptibility of hematopoietic stem cells (HSCs) to ex vivo genetic manipulation. To overcome this obstacle a high-throughput screen was performed to identify compounds that could
Autor:
Boi Quach, Linlin Guo, Zheng Pan, Olivier Dalmas, Barbara Sennino, Robert Bao, Michael T. Bethune, Katherine Heeringa, Salemiz Sandoval, Duo An, John Sorfleet, Robert Moot, Benjamin Yuen, Songming Peng, Andrew Conroy, Bhamini Purandare, Diana Nguyen, Corey Meadows, Michael Yi, Alex Franzusoff, Kyle Jacoby, Stefanie Mandl, Adam J. Litterman, William Lu
Publikováno v:
Cancer Research. 79:1435-1435
T cells capable of targeting neoepitopes (neoE) from tumor-specific mutations hold the potential to uniquely recognize and kill tumor cells. However, most cancer patients fail to mount a sufficient intrinsic T cell immune response to translate into c
Autor:
Stefanie Mandl, Songming Peng, Kyle Jacoby, Andrew Conroy, Fabrizia Urbinati, Tim Park, Diana Nguyen, Alex Franzusoff, Bhamini Purandare, Michael T. Bethune, Olivier Dalmas, Susan P. Foy, Theresa Hunter, Adam J. Litterman, Barbara Sennino, Robert Moot, William Lu
Publikováno v:
Cancer Research. 79:1433-1433
Clinical benefit observed with immuno-oncology trials often depends on the unleashing of a pre-existing intrinsic T cell immune response in each cancer patient. The targets of these intrinsic T cells are commonly ascribed to recognition of patient-sp